The efficacy of VVZ-149 in the treatment of the affective component of pain after laparoscopic colorectal surgeries

https://www.massgeneral.org/dcr/Assets/Files/AbstractBook2018.pdf

결론을 보면 VVZ-149를 투여받은 환자들이 24시간 동안 거의 50% 적은 OPIOID를 사용함. 

10월 4일 발표 자료... 향후 주가 전망은 예측할 수 없지만 개인적인 생각으로는 여유자금 있을때 마다 매수 전략

=======================================================

Results: Eighty subjects were screened, twenty were screen fails; 60 subjects were enrolled, 40 received VVZ-149 and 20

received placebo. The data from 7 subjects was excluded due to failure to meet study inclusion/exclusion criteria, and one

outlier was removed, for a total of 52 analyzed subjects (36 who received study drug, 16 who received placebo). Results

were compared between VVZ group and placebo group as well as between the subjects who received rescue doses (Rescue

group) and those who did not receive rescue doses (Non-Rescue group). The results showed non-significant differences in

pain intensity between the VVZ and placebo groups. There was a decrease of 34% in opioid use over the 24 hours for those

in the VVZ-149 group over placebo, although this decrease not significant. Those in the Rescue group were noted to have

higher HADS anxiety-depression scores and Pain Catastrophizing (PCS) scores. Rescue group patients were found to have

a positive correlation between pre-dose pain intensity (the pain score taken upon arrival in the PACU) and HADS anxiety

score. Individuals in the Rescue group who received VVZ-149 had lower total opioid consumption in the first 9 hours.

In patients who required Rescue dosing, For those patients in the Rescue group who were in the placebo arm, the pain intensity

remained greater or equal to 4 through the first 24 hours post operatively. Patients In the Rescue group who received placebo

also showed higher levels of total opioid consumption compared to those who received VVZ-149.

Conclusion: The results show that subjects who received VVZ-149 instead of placebo had a non-significant reduction in pain intensity while using almost 50% less opioids over 24 hours without an increase in adverse events. 

As all subjects were able to use IV PCA and self-titrate opioids in the postoperative period, this allowed for pain intensity to be reduced similarly between the two groups. Analysis of subjects’ HADS scores indicates that anxiety was a major contributor for patients to

receive Rescue doses of opioid in addition to PCA self-dosing. This suggests an association between anxiety, pain intolerance,

and higher levels of opioid consumption. Individual differences when reporting pain intensity are likely modulated by the

affective component of pain. In the group of patient who required Rescue dosing of opioids, which correlated to higher levels

of anxiety, the subjects who received VVZ-149 used less opioids and had lower pain intensities compared to subjects who

received placebo. This indicates that one of the mechanisms of action of VVZ-149 may be to decrease the negative affective

state of pain, leading to a decrease in the use of opioids in the postoperative period.